Department of Pathology, Stanford University, Stanford, CA 94305, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
Department of Pathology, Stanford University, Stanford, CA 94305, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA.
Cancer Cell. 2024 Jun 10;42(6):1018-1031.e6. doi: 10.1016/j.ccell.2024.05.004. Epub 2024 May 30.
Tumor metastasis requires systemic remodeling of distant organ microenvironments that impacts immune cell phenotypes, population structure, and intercellular communication. However, our understanding of immune phenotypic dynamics in the metastatic niche remains incomplete. Here, we longitudinally assayed lung immune transcriptional profiles in the polyomavirus middle T antigen (PyMT) and 4T1 metastatic breast cancer models from primary tumorigenesis, through pre-metastatic niche formation, to the final stages of metastatic outgrowth at single-cell resolution. Computational analyses of these data revealed a TLR-NFκB inflammatory program enacted by both peripherally derived and tissue-resident myeloid cells that correlated with pre-metastatic niche formation and mirrored CD14 "activated" myeloid cells in the primary tumor. Moreover, we observed that primary tumor and metastatic niche natural killer (NK) cells are differentially regulated in mice and human patient samples, with the metastatic niche featuring elevated cytotoxic NK cell proportions. Finally, we identified cell-type-specific dynamic regulation of IGF1 and CCL6 signaling during metastatic progression that represents anti-metastatic immunotherapy candidate pathways.
肿瘤转移需要对远处器官微环境进行系统性重塑,这会影响免疫细胞表型、群体结构和细胞间通讯。然而,我们对转移灶中免疫表型动态变化的理解仍不完整。在这里,我们以单细胞分辨率,从原发性肿瘤发生,到前转移灶形成,再到转移灶最终生长的阶段,对 Polyomavirus Middle T Antigen (PyMT) 和 4T1 转移性乳腺癌模型中的肺部免疫转录谱进行了纵向分析。对这些数据的计算分析揭示了一个 TLR-NFκB 炎症程序,该程序由外周衍生和组织驻留的髓样细胞执行,与前转移灶形成相关,并与原发性肿瘤中的 CD14“激活”髓样细胞相呼应。此外,我们观察到在小鼠和人类患者样本中,原发性肿瘤和转移灶自然杀伤 (NK) 细胞的调控存在差异,转移灶中具有更高比例的细胞毒性 NK 细胞。最后,我们确定了 IGF1 和 CCL6 信号在转移进展过程中的细胞类型特异性动态调节,这代表了抗转移免疫治疗的候选途径。
Cancer Cell. 2024-6-10
bioRxiv. 2023-5-7
Int J Cancer. 2019-5-13
Cancer Res. 2014-7-17
Breast Cancer Res. 2015-3-27
Pharmaceuticals (Basel). 2025-6-26
MedComm (2020). 2025-6-3
Cancer Cell. 2025-5-12
Genome Biol. 2024-1-30
Nat Biotechnol. 2024-2
Cancer Cell. 2023-3-13
Bioinformatics. 2022-10-14